Zicpalm 100 Capsule contains Itraconazole 100 mg, an antifungal agent belonging to the triazole class, indicated for the treatment of a wide range of fungal infections. Itraconazole exerts its therapeutic effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Zicpalm 100 is commonly prescribed for systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. The capsule formulation facilitates oral administration with good bioavailability, although absorption may be influenced by gastric pH and food intake. It is essential to adhere to the prescribed dosage regimen to ensure optimal therapeutic outcomes and minimize the risk of resistance development. Caution is advised in patients with hepatic impairment, as itraconazole is metabolized primarily via the liver cytochrome P450 system, and hepatotoxicity has been reported. Drug interactions are notable, particularly with medications metabolized by CYP3A4, necessitating careful review of concomitant therapies. Common adverse effects include gastrointestinal disturbances, headache, and rash. Zicpalm 100 should be used under medical supervision, with appropriate monitoring of liver function and clinical response to therapy.